Inventor
NEWMAN-TANCREDI ADRIAN
FR18 patents
⚠️ This page may combine multiple inventors who share the name “NEWMAN-TANCREDI ADRIAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ADIR
11 patentsUS6153625ANov 28, 2000
Indan-1-ol compounds
ADIR27 citations92
US5958927ASep 28, 1999
Indanol compounds
ADIR22 citations92
US5684020ANov 4, 1997
Piperazine, piperidine and 1,2,5,6-tetrahydropyridine
ADIR23 citations91
US5919784AJul 6, 1999
Heterocyclic aminomethyl compounds
ADIR25 citations90
US6127396AOct 3, 2000
Imidazoline compounds
ADIR8 citations73
US5753662AMay 19, 1998
Piperazine compounds
ADIR13 citations73
US5723484AMar 3, 1998
Benzopyran compounds as 5-HT2C receptor antagonists
ADIR7 citations73
US5663191ASep 2, 1997
Benzopyran compounds as 5HT2C receptor antagonists
ADIR14 citations73
US6172097B1Jan 9, 2001
Spiro imidazoline compounds
ADIR2 citations62
US6060487AMay 9, 2000
Indanol compounds
ADIR3 citations62
US6107345AAug 22, 2000
Benzocyclobutane compounds
ADIR0 citations41
PF MEDICAMENT
3 patentsUS11090298B2Aug 17, 2021
Method for treating movement disorders with befiradol
PF MEDICAMENT2 citations68
US10548885B2Feb 4, 2020
Method for treating movement disorders with befiradol
PF MEDICAMENT2 citations68
US12472169B2Nov 18, 2025
Method for treating movement disorders with befiradol
PF MEDICAMENT0 citations58
NEUROLIXIS
3 patentsUS11974992B2May 7, 2024
Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
NEUROLIXIS0 citations53
US10562853B2Feb 18, 2020
Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors
NEUROLIXIS0 citations43
US11191758B2Dec 7, 2021
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
NEUROLIXIS0 citations38